FSD Pharma Sets Date for Annual Meeting
January 22 2021 - 4:30PM
Business Wire
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (“FSD Pharma” or the
“Company”) today announced that it will hold its annual meeting of
shareholders (the “Meeting”) on June 29, 2021.
The Meeting will address normal course matters, including the
presentation of the Company’s audited financial statements, as well
as matters contained in a requisition for a special meeting
submitted to the Company by certain shareholders of the Company
claiming to hold in excess of 5.1% of the Company’s class B
subordinated voting shares, including two directors of the Company.
These shareholders are seeking to reduce the size of the Company’s
board of directors to five, and to replace six of the incumbent
directors with three directors selected by such shareholders.
Addressing all such matters at a single meeting will spare the
shareholders of the Company the additional costs and distraction
that would be associated with holding two separate meetings in
quick succession.
Shareholders are not required to take any action at this time in
respect of the Meeting. Shareholders will receive detailed
information about the matters presented at the Meeting in a
management information circular in early June, 2021.
About FSD Pharma FSD Pharma Inc. is a publicly-traded
holding company.
FSD Pharma BioSciences, Inc., a wholly-owned subsidiary, is a
specialty biotech pharmaceutical R&D company focused on
developing over time multiple applications of its lead compound,
FSD201, by down-regulating the cytokines to effectuate an
anti-inflammatory response.
The Company filed an IND with the FDA on August 28, 2020 and was
approved on September 25, 2020 to initiate a phase 2 clinical trial
for the use of FSD201 to treat COVID-19, the disease caused by the
SARS-CoV-2 virus.
Severe COVID-19 is characterized by an over-exuberant
inflammatory response that may lead to a cytokine storm and
ultimately death. The Company is focused on developing FSD201 for
its anti-inflammatory properties to avoid the cytokine storm
associated with acute lung injury in hospitalized COVID-19
patients.
Forward-Looking Statements Neither the Canadian
Securities Exchange nor its regulation services provider accept
responsibility for the adequacy or accuracy of this press
release.
Certain statements contained in this press release constitute
“forward-looking information” and “forward-looking statements”
within the meaning of applicable Canadian and U.S. securities laws
(collectively, “Forward-Looking Information”). Forward-Looking
Information includes, but is not limited to, information with
respect to FSD Pharma's strategy, plans or future financial or
operating performance, receipt of any FDA approvals, the completion
of any trials regarding the use of FSD201 to treat COVID-19, the
safety of FSD201 or whether FSD201 may be effective in treating
COVID-19, the costs associated with such planned trials and our
belief that we have sufficient cash to complete the Phase 2 study,
our ability to obtain required funding and the terms and timing
thereof, the ultimate development of any FDA approved synthetic
compounds, the expected insurance recovery related to the
settlement agreement, the completion of the settlement contemplated
in the settlement agreement and the timing and closing of the sale
of certain non-core real estate assets. The use of words such as
“budget”, “intend”, “anticipate”, “believe”, “expect”, “plan”,
“forecast”, “future”, “target”, “project”, “capacity”, “could”,
“should”, “focus”, “proposed”, “scheduled”, “outlook”, “potential”,
“estimate” and other similar words, and similar expressions and
statements relating to matters that are not historical facts, or
statements that certain events or conditions “may” or “will” occur,
are intended to identify Forward-Looking Information and are based
on FSD Pharma’s current beliefs or assumptions as to the outcome
and timing of such future events. Such beliefs or assumptions
necessarily involve known and unknown risks and uncertainties that
could cause actual results to differ materially from those
expressed or implied in such Forward‐Looking Information. Certain
of these risks and uncertainties are described in the Company’s
continuous disclosure filings available under the Company’s SEDAR
profile at www.sedar.com and under the Company’s EDGAR profile at
www.sec.gov. Forward‐Looking Information is not a guarantee of
performance. The Forward-Looking Information contained in this
press release is made as of the date hereof, and FSD Pharma is not
obligated to update or revise any Forward- Looking Information,
whether as a result of new information, future events or otherwise,
except as required by law. Because of the risks, uncertainties and
assumptions contained herein, investors should not place undue
reliance on Forward Looking-Information. The foregoing statements
expressly qualify any Forward-Looking Information contained
herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210122005455/en/
Donal Carroll, Chief Financial Officer, FSD Pharma Inc.
Dcarroll@fsdpharma.com
Investor Relations IR@fsdpharma.com
FSD Pharma (NASDAQ:HUGE)
Historical Stock Chart
From Aug 2024 to Sep 2024
FSD Pharma (NASDAQ:HUGE)
Historical Stock Chart
From Sep 2023 to Sep 2024